Sepracor, Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, has focused their efforts on treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products designed to serve large and growing markets. The company’s drug development program has proven its success by yielding a portfolio of pharmaceutical products and candidates. The focus of the program is on treating respiratory and central nervous system (CNS) disorders. For further information, visit the Company’s web site at www.sepracor.com.
- 17 years ago
QualityStocks
Sepracor, Inc. (NASDAQ: SEPR)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
The global rare disease treatment market was estimated at $195.2 billion in 2024 and is…
-
Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Is ‘One to Watch’
High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising…
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Appoints Industry Veteran Jon Bond to Board of Directors
Onar (OTCQB: ONAR) announced the appointment of marketing pioneer Jon Bond to its board of…